UBS Group’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-487
| Closed | -$8.87K | – | 10509 |
|
|
2024
Q2 | $8.87K | Sell |
487
-501
| -51% | -$9.16K | ﹤0.01% | 7773 |
|
|
2024
Q1 | $18.2K | Buy |
988
+442
| +81% | +$8.22K | ﹤0.01% | 6964 |
|
|
2023
Q4 | $10.7K | Buy |
+546
| New | +$9.53K | ﹤0.01% | 7428 |
|
|
2023
Q3 | – | Sell |
-3,263
| Closed | -$67.2K | – | 10200 |
|
|
2023
Q2 | $67.2K | Buy |
3,263
+2,453
| +303% | +$51.4K | ﹤0.01% | 6296 |
|
|
2023
Q1 | $16.6K | Sell |
810
-2,034
| -72% | -$45.5K | ﹤0.01% | 7230 |
|
|
2022
Q4 | $63.7K | Buy |
2,844
+1,205
| +74% | +$27.2K | ﹤0.01% | 6535 |
|
|
2022
Q3 | $34K | Buy |
1,639
+1,153
| +237% | +$28.1K | ﹤0.01% | 6746 |
|
|
2022
Q2 | $11K | Sell |
486
-1,658
| -77% | -$39.5K | ﹤0.01% | 7881 |
|
|
2022
Q1 | $59K | Buy |
2,144
+1,901
| +782% | +$53.5K | ﹤0.01% | 6340 |
|
|
2021
Q4 | $9K | Sell |
243
-1,706
| -88% | -$63.9K | ﹤0.01% | 8958 |
|
|
2021
Q3 | $80K | Buy |
1,949
+1,437
| +281% | +$60.6K | ﹤0.01% | 5990 |
|
|
2021
Q2 | $20K | Sell |
512
-914
| -64% | -$34.1K | ﹤0.01% | 7355 |
|
|
2021
Q1 | $51K | Buy |
1,426
+150
| +12% | +$5.63K | ﹤0.01% | 6533 |
|
|
2020
Q4 | $40K | Buy |
1,276
+958
| +301% | +$29.2K | ﹤0.01% | 6391 |
|
|
2020
Q3 | $9K | Buy |
+318
| New | +$9.35K | ﹤0.01% | 6971 |
|
Other funds holding GERM
UBS Group's GERM Position: Q3 2024 in Review
UBS Group sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 487 shares — an estimated $8.87K sold.
UBS Group first reported a position in GERM in Q3 2020 and held it in 15 quarters. The position peaked at $80K in Q3 2021. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.
- UBS Group reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
- UBS Group sold 487 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $8.87K.
- UBS Group first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 15 quarters.
- UBS Group's Amplify Treatments, Testing and Advancements ETF position peaked at $80K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.